从实验研究到计算方法:设计新型治疗方法的最新趋势,用于粉样蛋白生成
Pooja Ghosh1, Agnibin Kundu2, Debabani Ganguly3
1Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies & Research (JISIASR) Kolkata, JIS University, GP Block, Sector-5, Salt Lake, Kolkata 700091, West Bengal, India. poojaghosh@jisiasr.org.
Journal of materials chemistry. B
|December 12, 2024
概括
氨基粉症是由错误折叠的蛋白质引起的,导致器官损伤和致命疾病. 本综述探讨了针对蛋白质聚合的实验和计算方法,旨在寻找新的治疗方法.
科学领域:
- 生物化学和分子生物学
- 病理学 病理学 病理学
- 药物发现 药物发现 药物发现
背景情况:
- 氨基化症涉及错误折叠的蛋白质的积累,导致器官损伤和严重疾病,包括神经退行性和非神经病变性疾病.
- 精确的分子机制驱动氨基粉症的发病机制仍然难以捉摸,阻碍了治疗的发展.
- 了解蛋白质聚合对于解决与粉样蛋白疾病相关的细胞毒性和细胞亡至关重要.
研究的目的:
- 审查和总结调节粉样蛋白聚合的实验和计算策略.
- 为了提供对粉样性粉症新兴治疗剂的概述.
- 讨论开发治疗蛋白质错折疾病的挑战和未来前景.
主要方法:
- 关于用于研究和调节蛋白质聚合的实验技术的综合文献综述.
- 对粉样蛋白形成和毒性应用的计算方法的分析.
- 针对粉样蛋白通路的新型治疗药物的最新进展的综合.
主要成果:
- 确定了一系列有效调节粉样蛋白聚合的实验和计算方法.
- 突出了有前途的新型治疗药物和策略.
- 讨论了将研究成果转化为临床应用的复杂性和潜在障碍.
结论:
- 结合实验和计算方法的综合方法为了解和治疗粉样化症提供了一个有希望的途径.
- 对蛋白质聚合机制的进一步研究对于开发有效的治疗干预措施至关重要.
- 该领域正在向创新的治疗策略迈进,以打击蛋白质错折疾病.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.6K
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
11.8K
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
